System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Géraldine Pignot is an expert in Urology at Institut Paoli-Calmettes (France). As of October 2026, ScienceLeadR ranks Géraldine Pignot in the top 1% of experts worldwide for Urinary Bladder Diseases, Urologic Neoplasms and Urogenital Neoplasms. Géraldine Pignot has authored 360 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 6 of them ongoing. SLR score: 1,346 (community average: 125). How the SLR is computed.

LeadR Profile

Géraldine Pignot Institut Paoli-Calmettes France
1 346 ScienceLeadR Reputation 1346

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Institute Paoli-Calmettes

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 360

Citations

Citations: 4 466 1st author: 69 Last author: 45 Unique author: 9

Main journals

Prog Urol 112
Eur Urol 25
J Clin Oncol 25
World J Urol 24
Progrès en urologie. Formation médicale continue/Progrès en urologie. FMC 16

Best Journals

J Clin Oncol 20
Lancet Oncol 3
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy.
PMID 42132947 — urinary bladder, urinary bladder neoplasms, hemoglobins, urology, anemia, neoplasms, drug therapy, cystectomy, prognosis, chemotherapy		World J Urol20260
Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.
PMID 42120219 — cells, urology, lymph nodes, carcinoma, renal cell, lymph		Eur Urol20260
Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer.
PMID 42000298 — registries, urinary bladder, urinary bladder neoplasms, muscles, neoplasms, multiple chronic conditions, therapeutics, non-muscle invasive bladder neoplasms		Eur Urol Oncol20260
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30).
PMID 41380977 — radiotherapy, urinary bladder, urinary bladder neoplasms, margins of excision, safety, neoplasms, radiotherapy, adjuvant, cystectomy, therapeutics		Radiother Oncol20250
Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort.
PMID 41322956 — cells, margins of excision, neoplasms, carcinoma, renal cell, lymph, therapeutics, prognosis		Eur Urol Open Sci20250

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 6
Phase 2 4
Phase 3 4
Phase 1/Phase 2 1

By status:

Active not recruiting 4
Completed 4
Recruiting 3
Unknown 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 13
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 1
multicentricup10 9

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Open label Multicenter Study Evaluating the Efficacy and Safety of TAR 210 Erdafitinib Intravesical Delivery System Versus Investigator s Choice of Intravesical Chemotherapy in Participants with High risk Non muscle invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette Gu rin (BCG)
2024-519493-39-00 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, bacillus, drug therapy, chemotherapy, non-muscle invasive bladder neoplasms		Phase 3Recruiting2025
A study comparing TAR 210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations
2023-507684-19-00 — urinary bladder, urinary bladder neoplasms, genes, safety, muscles, neoplasms, drug therapy, therapeutics, chemotherapy, non-muscle invasive bladder neoplasms		Phase 3Active not recruiting2024
A Phase 3 Randomized Open label Multi center Study Evaluating the Efficacy and Safety of TAR 200 Versus Investigator s Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette Gu rin (BCG) and Recurred with High risk Non Muscle Invasive Bladder Cancer (HR NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
2023-507685-10-00 — urinary bladder, urinary bladder neoplasms, safety, muscles, neoplasms, multiple chronic conditions, bacillus, drug therapy, cystectomy, chemotherapy, non-muscle invasive bladder neoplasms		Phase 3Active not recruiting2024
Interest of Magnetic Resonance Imaging in the Diagnosis of Upper Urinary Tract Invasive Tumours
NCT07252882 — contrast media, urinary tract, tomography, neoplasms, magnetic resonance imaging, urologic neoplasms, diagnosis		N/ANot yet recruiting2025
Multicentric Prospective T1 Urinary Bladder Cancer Registry
NCT05792033 — registries, urinary bladder, urinary bladder neoplasms, pathologists, neoplasms, pathology, privacy, cystectomy, diagnosis, therapeutics, prognosis		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS